Navigation Links
Baxter's Board of Directors Approves New Share Repurchase Authorization of $2 Billion
Date:3/18/2008

DEERFIELD, Ill., March 18 /PRNewswire-FirstCall/ -- Baxter International Inc. (NYSE: BAX) announced today that its Board of Directors has approved the repurchase of an additional $2 billion of the company's common stock to be executed upon completion of the company's existing share repurchase authorization.

Baxter has less than $700 million of remaining authorization under its previous $2 billion share repurchase program that was authorized in March 2007. Shares will be repurchased in the open market at times and amounts determined by management based on its evaluation of market conditions and other factors.

In 2007, Baxter returned more than $2.5 billion to shareholders through both share repurchases and dividends. The company repurchased 34 million shares of common stock, for approximately $1.9 billion, and paid dividends totaling $704 million.

"We remain confident in our ongoing ability to generate strong cash flows," said Robert M. Davis, chief financial officer. "We expect to return significant value to shareholders through a disciplined approach to capital allocation and financial management, while accelerating our investment in R&D and new business development opportunities that position us for future growth."

Baxter International Inc., through its subsidiaries, assists healthcare professionals and their patients with the treatment of complex medical conditions, including hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other conditions. The company applies its expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients' lives.

This release includes forward-looking statements concerning the company's expected cash
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
2. KGI Elects Three New Members to Board of Trustees
3. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
4. DOV Pharmaceutical, Inc. Begins Trading on OTC Bulletin Board
5. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
6. BioLife Solutions Expands Scientific Advisory Board
7. NeurogesX Appoints New Director to the Board
8. Genstar Names Michael Hurt to Its Strategic Advisory Board
9. Boston Scientific Announces Election of Ray Elliott to Its Board of Directors
10. Bruce Pasternack Elected to Codexis Board
11. Interleukin Genetics Announces Management and Board Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... announced data presentations on its novel oral JAK2 inhibitor, ... Meeting and Exposition in New Orleans. ,, Data will ... 1 dose-escalation trial of SB1518 detailing its safety, tolerability ... 100 to 600 mg. These doses were administered once ...
(Date:12/2/2009)... /PRNewswire-Asia/ -- Simcere Pharmaceutical Group,("Simcere" or the "Company") ... company,specializing in the development, manufacturing, and marketing of ... that 105 of,its drugs have been included in ... by China,s Ministry of Human Resources and Social,Security ...
(Date:12/2/2009)... -- The world is going through,extraordinary times; markets are ... industries. It turns out that the pharma industry has ... take a,vacation. , During the ... Johnson & Johnson inaugurated an R&D center in Shanghai, ...
(Date:12/2/2009)... Dec. 2 According to the National Institute of Health, ... already have some stage of diabetic retinopathy. Diabetic retinopathy, ... a major cause of blindness in people with diabetes and ... fact, up to 80 percent of all patients who,ve had ...
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4
... Diffusion Pharmaceuticals LLC, a clinical-stage drug development company ... announced the completion of a $2.9 million private ... overall growth and clinical programs for its lead ... In addition, David G. Kalergis, Chief Executive Officer ...
... /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,Inc. ("China Sky ... CSKI ), a leading,fully integrated pharmaceutical company producing ... today announced that the Company,s,Chief Financial Officer, Mr. ... at the upcoming Roth 21st Annual OC Growth ...
... Fla., Feb. 6 Tigris Pharmaceuticals, Inc., a ... it has filed an Investigational New Drug (IND) ... (FDA) for GGTI-2418, a novel anticancer compound. ... I (GGTase I) that appears to induce apoptosis ...
Other Biology Technology:Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida 2Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida 3China Sky One Medical, Inc. CFO to Present at Roth Conference 2China Sky One Medical, Inc. CFO to Present at Roth Conference 3Tigris Pharmaceuticals Files IND Application for GGTI-2418 2Tigris Pharmaceuticals Files IND Application for GGTI-2418 3
(Date:12/2/2009)... evidence that people who smoke cigarettes over a long ... colorectal cancer, even after adjusting for other risk factors. ... smoke, or to quit as soon as possible," said ... emeritus, epidemiology and surveillance research at the American Cancer ...
(Date:12/2/2009)... first cigarette within minutes after waking up have much higher ... the body, than those who wait to smoke, regardless of ... cotinine levels appear to reflect the risk of lung cancer, ... may be especially at risk for lung cancer," said researcher ...
(Date:12/2/2009)... secondhand smoke for a prolonged period of time and ... cancer, even in women who never smoked cigarettes themselves. ... smoke could increase risk of breast cancer is one ... scientist at the Northern California Cancer Center,s Berkeley office. ...
Breaking Biology News(10 mins):Cigarette smoking increases colorectal cancer risk 2Increased nicotine levels detected in those who light-up earlier 2Exposure to secondhand cigarette smoke over a lifetime increased breast cancer risk later in life 2Indoor Tanning 3A The Risks of Ultraviolet Rays 62260 1Advanced Health Media Honored at NJ Finest Award Ceremony 62257 1Advanced Health Media Honored at NJ Finest Award Ceremony 62257 2ISMPP Announces Publication of Good Publication Practice for Communicating Company Sponsored Medical Research 3A GPP2 Guidelines Published in the BMJ 15000 1ISMPP Announces Publication of Good Publication Practice for Communicating Company Sponsored Medical Research 3A GPP2 Guidelines Published in the BMJ 15000 2ISMPP Announces Publication of Good Publication Practice for Communicating Company Sponsored Medical Research 3A GPP2 Guidelines Published in the BMJ 15000 3
... Severely restricting calories leads to a longer life, scientists ... the first time that such a diet also can ... inevitable progression to physical disability and loss of independence., ... restriction, showed that the diet reduces the amount of ...
... United States, smart growth proponents have urged communities to ... standard and familiar sprawl. Cluster developments create a ... portion of the land area than dispersed houses. ... open space, farmland, and rural character. Yet few ...
... ARANSAS, Texas University of Texas at Austin marine scientists ... Atmospheric Association (NOAA) to better understand how nutrient pollution ... low oxygen water called the Dead Zone in the ... and recreationally important fish and shellfish. , The funds ...
Other Biology News:Severely restricted diet linked to physical fitness into old age 2Location, location, location 2Location, location, location 3Gulf of Mexico dead zone to be studied by University of Texas at Austin marine scientists 2
Co-precipitant is free of background polynucleotides,Dnases,Rnases, proteases. 20mg/ml...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
RAB32, member RAS oncogene family, mRNA (cDNA clone MGC:13500 IMAGE:4280407), complete cds...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
Biology Products: